News | Heart Failure | July 13, 2017

Biotronik Hosts Heart Failure Symposium at Europace-Cardiostim 2017

Studies highlight questions on avoiding ICD therapy, rate-adaptive pacing and the role of home monitoring

Biotronik Hosts Heart Failure Symposium at Europace-Cardiostim 2017

July 13, 2017 — Experts in heart failure management gathered in June to discuss varying scientific evidence in their field and how to transfer results into clinical practice. The Biotronik symposium “CRT in 2017: Remaining Challenges and New Opportunities in Heart Failure Management” took place at the Europace-Cardiostim 2017 congress, June 18-21 in Vienna, Austria.

One challenge is the limited data on whether to exchange cardiac resynchronization therapy defibrillators (CRT-Ds) for pacemakers (CRT-Ps) during routine device replacements in patients who responded well to therapy with improved hemodynamics. Jacques Mansourati, M.D., University of Western Brittany, Brest, France, is using the BioContinue study to help define the profile of CRT responders who may no longer need an implantable cardioverter defibrillator (ICD).

Between 20 to 40 percent of CRT patients suffer from chronotropic incompetence, representing a potentially high need for rate-adaptive pacing. At the same time, there is a lack of evidence about the effectiveness of accelerometer rate adaption — current guidelines do not include a recommendation. Mattias Roser, M.D., Charité Hospital, Berlin, Germany, is conducting a pilot study to research if rate-adaptive pacing with Closed Loop Stimulation (CLS) improves clinical outcomes. The primary endpoint is ventilatory efficiency – a cardio-pulmonary exercise test’s most reliable prognostic variable.

“Although available for decades, there is still conflicting evidence on whether an accelerometer, which measures patients’ movements, is clinically beneficial,” explained Roser. “We believe that CLS has the potential to significantly improve CRT patient outcomes as it reflects individual metabolic demand and reacts to the heart’s contractility. CLS from Biotronik is the only technology to respond to mental as well as physical stress.”

Physicians also discussed the benefits of Biotronik Home Monitoring for CRT patients. Guidelines recommend remote monitoring since the IN-TIME study demonstrated a significant reduction in mortality with Home Monitoring. Interestingly, when the Biotronik system was excluded from trials, such as REM-HF, More-CARE and Opti-Link HF, no clinical benefits of remote monitoring were found. The differences in study results can be explained by Home Monitoring’s features, according to the company: a multi-parameter analysis of relevant clinical data and highly-reliable daily data transfer. With efficient in-clinic workflow, Home Monitoring can prevent heart failure progression and reduce mortality as demonstrated by Hindricks et. al in the recent TRUECOIN meta-analysis.

For more information: www.biotronik.com


Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
Subscribe Now